| Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New england journal of medicine 376 (3), 209-220, 2017 | 1873 | 2017 |
| Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017 | 1775 | 2017 |
| The Parkinson progression marker initiative (PPMI) K Marek, D Jennings, S Lasch, A Siderowf, C Tanner, T Simuni, C Coffey, ... Progress in neurobiology 95 (4), 629-635, 2011 | 1483 | 2011 |
| SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy NA Naryshkin, M Weetall, A Dakka, J Narasimhan, X Zhao, Z Feng, ... science 345 (6197), 688-693, 2014 | 547 | 2014 |
| Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite M Platten, PP Ho, S Youssef, P Fontoura, H Garren, EM Hur, R Gupta, ... Science 310 (5749), 850-855, 2005 | 517 | 2005 |
| A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease S Ostrowitzki, RA Lasser, E Dorflinger, P Scheltens, F Barkhof, ... Alzheimer's research & therapy 9, 1-15, 2017 | 469 | 2017 |
| The Global Adherence Project (GAP): A multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis V Devonshire, Y Lapierre, R Macdonell, C Ramo‐Tello, F Patti, ... European Journal of Neurology 18 (1), 69-77, 2011 | 414 | 2011 |
| Heme oxygenase–1 and carbon monoxide suppress autoimmune neuroinflammation ÂA Chora, P Fontoura, A Cunha, TF Pais, S Cardoso, PP Ho, LY Lee, ... The Journal of clinical investigation 117 (2), 438-447, 2007 | 362 | 2007 |
| Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis WH Robinson, P Fontoura, BJ Lee, HEN De Vegvar, J Tom, R Pedotti, ... Nature biotechnology 21 (9), 1033-1039, 2003 | 294 | 2003 |
| Risdiplam in type 1 spinal muscular atrophy G Baranello, BT Darras, JW Day, N Deconinck, A Klein, R Masson, ... New England Journal of Medicine 384 (10), 915-923, 2021 | 293 | 2021 |
| Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review A Langer-Gould, RA Popat, SM Huang, K Cobb, P Fontoura, MK Gould, ... Archives of neurology 63 (12), 1686-1691, 2006 | 281 | 2006 |
| A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease S Salloway, M Farlow, E McDade, DB Clifford, G Wang, JJ Llibre-Guerra, ... Nature medicine 27 (7), 1187-1196, 2021 | 221 | 2021 |
| Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway H Garren, PJ Ruiz, TA Watkins, P Fontoura, LVT Nguyen, ER Estline, ... Immunity 15 (1), 15-22, 2001 | 186 | 2001 |
| Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis G Klein, P Delmar, N Voyle, S Rehal, C Hofmann, D Abi-Saab, ... Alzheimer's research & therapy 11, 1-12, 2019 | 182 | 2019 |
| Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls BT Darras, R Masson, M Mazurkiewicz-Bełdzińska, K Rose, H Xiong, ... New England Journal of Medicine 385 (5), 427-435, 2021 | 176 | 2021 |
| Trial of prasinezumab in early-stage Parkinson’s disease G Pagano, KI Taylor, J Anzures-Cabrera, M Marchesi, T Simuni, K Marek, ... New England Journal of Medicine 387 (5), 421-432, 2022 | 170 | 2022 |
| Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination R Pedotti, JJ DeVoss, S Youssef, D Mitchell, J Wedemeyer, R Madanat, ... Proceedings of the National Academy of Sciences 100 (4), 1867-1872, 2003 | 162 | 2003 |
| Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects C Sievers, M Meira, F Hoffmann, P Fontoura, L Kappos, RLP Lindberg Clinical immunology 144 (1), 70-79, 2012 | 155 | 2012 |
| Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial E Bertini, E Dessaud, E Mercuri, F Muntoni, J Kirschner, C Reid, ... The Lancet Neurology 16 (7), 513-522, 2017 | 131 | 2017 |
| Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled … E Mercuri, N Deconinck, ES Mazzone, A Nascimento, M Oskoui, K Saito, ... The Lancet Neurology 21 (1), 42-52, 2022 | 130 | 2022 |
lawrence steinmanstanford universityПотвърден имейл адрес: stanford.edu
